RegulatoryJul 10, 2026, 08:33 AM
Clearmind Responds to HHS RFI on MEAI for Alcohol Use Disorder
AI Summary
Clearmind Medicine Inc. announced it has submitted a formal response to the U.S. Department of Health and Human Services (HHS) Request for Information (RFI). The submission highlights the potential of its MEAI-based candidate, CMND-100, as an innovative, non-hallucinogenic neuroplastogen for the treatment of Alcohol Use Disorder (AUD) and binge behaviors. Clearmind proposes an inexpensive, scalable, and clinically effective treatment model, emphasizing the drug's low abuse potential and ability to support moderation and long-term recovery for the approximately 10% of the U.S. population affected by AUD.
Key Highlights
- Submitted a formal response to the U.S. Department of Health and Human Services (HHS) Request for Information (RFI).
- Response concerns MEAI's potential as an intervention for addiction, specifically Alcohol Use Disorder (AUD).
- Proposes an innovative model for inexpensive, scalable, and clinically effective AUD treatment.
- Highlights proprietary MEAI-based candidate CMND-100, a non-hallucinogenic neuroplastogen for AUD.
- Emphasizes AUD affects approximately 10% of the U.S. population, with only 1 in 10 receiving treatment.
- MEAI is positioned as a scalable, at-home solution with low abuse potential, engaging neural pathways like 5-HT1A.
- Research at Yale and Johns Hopkins indicates MEAI is well-positioned for addiction treatment efforts.
Price Impact
More from CMND